Block and tackle: CTLA4Ig takes on lupus.
Blockade of antigen nonspecific costimulatory signals is a promising approach for the treatment of autoimmune diseases including systemic lupus erythematosus (SLE). CTLA4Ig, an antagonist of the CD28/B7 costimulatory interaction, effectively prevents SLE onset in several murine models and, when used in combination with cyclophosphamide, can induce remission of active SLE nephritis. In this review we describe the known mechanisms of action of CTLA4Ig both in normal immunity and in autoimmune disease models and address issues about its activity that still need to be resolved. We discuss the preclinical use of CTLA4Ig in murine SLE models and the rationale for a clinical trial in SLE patients.
Davidson
A
A
Department of Medicine, Columbia University, New York, NY, USA. ad2247@columbia.edu
Diamond
B
B
Wofsy
D
D
Daikh
D
D
D000069594:Abatacept; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D018796:Immunoconjugates; D000069594:Abatacept